A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

• Status: NOT_YET_RECRUITING
• Trial end date: 2031-10-16

Summary

The purpose of this study is to evaluate the efficacy and safety of Liso-cel compared to standard of care in adults with Relapsed or Refractory Follicular Lymphoma.

• Phase: PHASE3

Details

• Lead Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
• Collaborator: Celgene Corporation
• Treatments: Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; fludarabine; Lenalidomide; Prednisone; Rituximab; Vincristine